Pitcairn Co. Grows Holdings in Pfizer Inc. (NYSE:PFE)

Pitcairn Co. increased its position in shares of Pfizer Inc. (NYSE:PFE) by 3.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 36,128 shares of the biopharmaceutical company’s stock after buying an additional 1,135 shares during the period. Pitcairn Co.’s holdings in Pfizer were worth $1,003,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Clifford Swan Investment Counsel LLC grew its holdings in Pfizer by 4.7% during the 4th quarter. Clifford Swan Investment Counsel LLC now owns 417,070 shares of the biopharmaceutical company’s stock worth $12,007,000 after acquiring an additional 18,611 shares in the last quarter. LifePlan Financial LLC acquired a new position in Pfizer during the 4th quarter worth $255,000. Cantor Fitzgerald Investment Advisors L.P. acquired a new position in Pfizer during the 4th quarter worth $16,166,000. KLCM Advisors Inc. boosted its holdings in shares of Pfizer by 75.0% in the 4th quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock valued at $5,004,000 after buying an additional 74,487 shares during the period. Finally, First Heartland Consultants Inc. boosted its holdings in shares of Pfizer by 43.3% in the 4th quarter. First Heartland Consultants Inc. now owns 13,013 shares of the biopharmaceutical company’s stock valued at $375,000 after buying an additional 3,933 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Trading Up 0.7 %

Shares of Pfizer stock traded up $0.20 during trading on Thursday, hitting $30.18. The company’s stock had a trading volume of 40,635,434 shares, compared to its average volume of 39,745,676. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $37.35. The stock has a market cap of $171.02 billion, a price-to-earnings ratio of -504.58, a price-to-earnings-growth ratio of 1.15 and a beta of 0.69. The stock has a 50-day moving average price of $28.47 and a two-hundred day moving average price of $27.75.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The company had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. During the same quarter in the prior year, the firm earned $1.23 EPS. The business’s revenue was down 19.5% on a year-over-year basis. Equities research analysts anticipate that Pfizer Inc. will post 2.39 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be issued a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 5.57%. The ex-dividend date is Friday, July 26th. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

Analysts Set New Price Targets

PFE has been the subject of a number of analyst reports. BMO Capital Markets reissued an “outperform” rating and set a $36.00 target price (up from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Barclays boosted their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 10th. Morgan Stanley boosted their target price on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a report on Thursday, May 2nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Wednesday, July 10th. Nine equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $34.50.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.